[Single versus double antiplatelet therapy following coronary artery bypass grafting]

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Interventional Cardiology

Background:

• Coronary artery bypass grafting (CABG) is crucial for complex obstructive coronary artery disease, especially in diabetics.
• Long-term CABG success hinges on anastomosis, conduit choice (arterial preferred), and preventing graft occlusion.
• Aspirin improves prognosis and bypass patency but doesn't fully prevent venous bypass occlusion.

Purpose of the Study:

• To evaluate the efficacy of dual antiplatelet therapy (DAPT) in preventing graft occlusion post-CABG.
• To assess the benefits and risks of combining aspirin with thienopyridines after saphenous vein revascularization.

Main Methods:

• Review of randomized controlled trials and meta-analyses on DAPT post-CABG.
• Analysis of clinical outcomes, bypass patency, and bleeding risk associated with DAPT.
• Focus on saphenous vein grafts and the early postoperative pro-thrombotic state.

Main Results:

• Aspirin alone improves prognosis but has limitations in preventing venous bypass occlusion (10-20% at 1 year, 50% at 10 years).
• DAPT has yielded conflicting results in trials, but recent meta-analyses suggest potential benefits.
• Wider use of DAPT for at least 6 months may reduce graft thrombosis, despite a slightly increased bleeding risk.

Conclusions:

• DAPT, combining aspirin with thienopyridines, warrants wider consideration for at least 6 months post-CABG, particularly for saphenous vein grafts.
• This strategy may mitigate the heightened pro-thrombotic and pro-inflammatory state in the early postoperative period.
• Balancing the benefits of reduced graft thrombosis against a potential increase in bleeding risk is crucial for patient selection.